a b s t r a c t
The relationship of cholesterol with stroke is much less clear than its relationship with myocardial infarction, thus confounding the interpretation of results with cholesterol-lowering trials (Di Napoli et al., 2002) [1] , (De Caterina et al., 2010) [2] ). IMPROVE-IT data ( ) [3] ), showing a 13.3% reduction in total cholesterol at one year in association with a hazard ratio (HR) of 0. i86 for total stroke during the trial, are very closely aligned with the relative risk of 0.90 predicted based on the totality of lipid lowering interventions [4] ). We here provide the data from the original trials used to construct this meta-analysis, with the now added additional data from IMPROVE-IT, well-fitting the previously found meta-regression line.
These data are important to predict stroke outcomes in currently ongoing trials now testing PCSK9 or cholesterol ester transfer protein inhibitors. & 2016 Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). These results now allow a prediction of the reduction in stroke in trials now testing the PCSK9 inhibitors and the cholesterol ester transfer protein (CETP) inhibitor anacetrapib.
Type of data

Data
Data provided here are the characteristics of source trials used for the construction of the metaregression of reduction in stroke as a function of reduction in total cholesterol.
Experimental design, materials and methods
We had previously carried out a meta-regression by using inverse variance weighted linear regression of the log RR for total stroke against the percent of TC reduction as the explanatory variable. Weights in each study were the reciprocals of the variances for the logarithm RR for stroke. The meta-regression had yielded the following equation: ln total stroke RR ð Þ ¼ 0:00518 À 0:00793 % TC reduction ð Þ
The regression coefficient for percent TC reduction was significantly different from zero (p ¼0.0017). This equation indicates that some benefit from cholesterol-lowering intervention on the risk of stroke can be expected when the percent reduction of serum cholesterol is 4 2-3%, the clinical benefit becoming statically significant when TC is reduced by $ 8%.
We have now compared the reduction in stroke observed in IMPROVE-IT [3] with that calculated from our previous meta-analysis of all lipid lowering interventions reporting effects on stroke, in all trials as previously reported and as shown in Table 1 . IMPROVE-IT [3] has now shown that a 13.3% reduction in total cholesterol at one year was associated with a hazard ratio (HR) of 0.86 for total stroke during the trial. This result is very closely aligned with the relative risk of 0.90 predicted on the basis of the totality of lipid lowering interventions [2, 5] . 
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